Edge Therapeutics, Inc. (EDGE) Upgraded to “Buy” by Zacks Investment Research
Zacks Investment Research upgraded shares of Edge Therapeutics, Inc. (NASDAQ:EDGE) from a sell rating to a buy rating in a report issued on Monday. The brokerage currently has $12.00 price target on the biotechnology company’s stock.
According to Zacks, “Edge Therapeutics, Inc. is a biotechnology company which discovers, develops and commercializes hospital-based therapies for acute life-threatening neurological conditions. Its lead product candidate which are in preclinical trial EG-1962, a polymer-based microparticle used for the treatment of aneurysmal subarachnoid hemorrhage, EG-1964, to prevent recurrent bleeding after treatment for cSDH and EG-1963, to prevent rebleeding following surgeries outside the brain. Edge Therapeutics, Inc. is headquartered in Berkeley Heights, New Jersey. “
Separately, BidaskClub cut shares of Edge Therapeutics from a buy rating to a hold rating in a report on Monday, August 14th.
Shares of Edge Therapeutics (NASDAQ EDGE) traded down $0.53 during mid-day trading on Monday, reaching $10.09. The company had a trading volume of 31,945 shares, compared to its average volume of 52,498. The company has a debt-to-equity ratio of 0.20, a quick ratio of 8.34 and a current ratio of 8.34. Edge Therapeutics has a 12 month low of $7.30 and a 12 month high of $13.50.
Edge Therapeutics (NASDAQ:EDGE) last issued its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.48) by $0.11. equities analysts anticipate that Edge Therapeutics will post -1.7 earnings per share for the current fiscal year.
WARNING: “Edge Therapeutics, Inc. (EDGE) Upgraded to “Buy” by Zacks Investment Research” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.watchlistnews.com/edge-therapeutics-inc-edge-upgraded-to-buy-by-zacks-investment-research/1686212.html.
In other news, CEO Brian A. Leuthner sold 2,500 shares of the company’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $10.37, for a total value of $25,925.00. Following the completion of the transaction, the chief executive officer now owns 117,736 shares in the company, valued at $1,220,922.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Brian A. Leuthner sold 7,500 shares of the company’s stock in a transaction that occurred on Friday, November 3rd. The shares were sold at an average price of $10.91, for a total transaction of $81,825.00. Following the completion of the transaction, the insider now owns 102,736 shares of the company’s stock, valued at approximately $1,120,849.76. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 38,500 shares of company stock valued at $409,465. Corporate insiders own 36.19% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the company. Franklin Resources Inc. boosted its holdings in shares of Edge Therapeutics by 1.1% in the second quarter. Franklin Resources Inc. now owns 2,663,123 shares of the biotechnology company’s stock valued at $27,324,000 after buying an additional 30,100 shares during the period. Janus Henderson Group PLC acquired a new position in shares of Edge Therapeutics in the second quarter valued at approximately $21,962,000. Vanguard Group Inc. boosted its holdings in shares of Edge Therapeutics by 2.9% in the first quarter. Vanguard Group Inc. now owns 700,003 shares of the biotechnology company’s stock valued at $6,377,000 after buying an additional 19,973 shares during the period. State Street Corp boosted its holdings in shares of Edge Therapeutics by 16.3% in the second quarter. State Street Corp now owns 277,352 shares of the biotechnology company’s stock valued at $2,847,000 after buying an additional 38,909 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Edge Therapeutics by 5.0% in the first quarter. Geode Capital Management LLC now owns 172,646 shares of the biotechnology company’s stock valued at $1,572,000 after buying an additional 8,181 shares during the period. Institutional investors own 49.29% of the company’s stock.
About Edge Therapeutics
Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.
Receive News & Ratings for Edge Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.